SG10201407947WA - Compressible-coated pharmaceutical compositions and tablets and methods of manufacture - Google Patents
Compressible-coated pharmaceutical compositions and tablets and methods of manufactureInfo
- Publication number
- SG10201407947WA SG10201407947WA SG10201407947WA SG10201407947WA SG10201407947WA SG 10201407947W A SG10201407947W A SG 10201407947WA SG 10201407947W A SG10201407947W A SG 10201407947WA SG 10201407947W A SG10201407947W A SG 10201407947WA SG 10201407947W A SG10201407947W A SG 10201407947WA
- Authority
- SG
- Singapore
- Prior art keywords
- compressible
- tablets
- manufacture
- methods
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
123534 v1/DC There is provided a method for preparing a pharmaceutical composition comprising compressible coated, taste-masked and/or controlled-release coated drug-containing particles, rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol, a saccharide, or a mixture thereof, and other optional, pharmaceutically acceptable excipients wherein the orally disintegrating tablet (ODT) or rapidly dispersing tablet (RDT) composition having acceptable tableting, organoleptic, and pharmacokinetic properties.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26521309P | 2009-11-30 | 2009-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201407947WA true SG10201407947WA (en) | 2015-01-29 |
Family
ID=44066882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201407947WA SG10201407947WA (en) | 2009-11-30 | 2010-11-23 | Compressible-coated pharmaceutical compositions and tablets and methods of manufacture |
Country Status (18)
Country | Link |
---|---|
US (1) | US20110129530A1 (en) |
EP (1) | EP2506835B1 (en) |
JP (1) | JP5854476B2 (en) |
AR (1) | AR079175A1 (en) |
AU (1) | AU2010324835B2 (en) |
BR (1) | BR112012012999A2 (en) |
CA (1) | CA2782177C (en) |
CL (1) | CL2012001404A1 (en) |
CO (1) | CO6551722A2 (en) |
ES (1) | ES2739888T3 (en) |
IL (1) | IL220037A0 (en) |
MX (1) | MX337603B (en) |
NZ (1) | NZ600123A (en) |
RU (1) | RU2012124265A (en) |
SG (1) | SG10201407947WA (en) |
TW (1) | TWI495491B (en) |
UY (1) | UY33062A (en) |
WO (1) | WO2011066287A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
JP2014526508A (en) | 2011-09-14 | 2014-10-06 | セルジーン コーポレイション | Cyclopropanecarboxylic acid {2-[(1S) -1- (3-ethoxy-4-methoxy-phenyl) -2-methanesulfonyl-ethyl] -3-oxo-2,3-dihydro-1H-isoindole-4 -Il} -amide formulations |
BR112014026439B1 (en) | 2012-04-27 | 2022-05-31 | Merck Patent Gmbh | Pharmaceutical formulation in the form of a coated tablet, and its preparation process |
HUE045603T2 (en) * | 2012-06-15 | 2020-01-28 | Pharmathen Sa | Pharmaceutical composition containing phosphate binding polymer |
WO2014066318A1 (en) | 2012-10-25 | 2014-05-01 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
WO2015023675A2 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
CN106102737B (en) | 2013-10-22 | 2019-06-14 | 综合医院公司 | Cromoglycic acid derivative and the correlation technique of imaging and treatment |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015120201A1 (en) | 2014-02-05 | 2015-08-13 | Kashiv Pharma, Llc | Abuse-resistant drug formulations with built-in overdose protection |
AU2015237721B2 (en) * | 2014-03-26 | 2018-04-26 | Sun Pharma Advanced Research Company Ltd. | Abuse deterrent immediate release coated reservoir solid dosage form |
EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
US20170209380A1 (en) * | 2014-07-30 | 2017-07-27 | Merck Patent Gmbh | Directly compressible composition comprising microcrystalline cellulose |
EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
TWI728172B (en) | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | Methods of treating eosinophilic esophagitis |
CN109922800B (en) | 2016-08-31 | 2023-06-13 | 通用医疗公司 | Macrophage/microglial cell in neuroinflammation related to neurodegenerative diseases |
BR112019012104A2 (en) * | 2016-12-14 | 2019-10-29 | Merck Patent Gmbh | directly compressible matrix for the production of extended release tablets of the active pharmaceutical principle |
JP7202376B2 (en) * | 2017-07-20 | 2023-01-11 | エーゼットセラピーズ, インコーポレイテッド | Cromolyn sodium and ibuprofen powder formulation |
EP3817739A4 (en) | 2018-07-02 | 2022-04-13 | The General Hospital Corporation | Powdered formulations of cromolyn sodium and ?-lactose |
GB202001237D0 (en) * | 2020-01-29 | 2020-03-11 | Sisteks D O O | Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product |
JP7482645B2 (en) * | 2020-02-18 | 2024-05-14 | 沢井製薬株式会社 | Method for producing granules containing core particles |
EP4298737A1 (en) | 2021-02-24 | 2024-01-03 | BlueHalo LLC | System and method for a digitally beamformed phased array feed |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5004595A (en) * | 1986-12-23 | 1991-04-02 | Warner-Lambert Company | Multiple encapsulated flavor delivery system and method of preparation |
JP2681601B2 (en) | 1993-11-01 | 1997-11-26 | 協和醗酵工業株式会社 | External lubrication type tablet press |
JP2841267B2 (en) * | 1993-12-17 | 1998-12-24 | エスエス製薬株式会社 | Ibuprofen-containing granules |
JPH09323934A (en) | 1996-05-31 | 1997-12-16 | Kanebo Ltd | Suppository having improved preservation stability |
ATE477793T1 (en) | 1996-06-14 | 2010-09-15 | Kyowa Hakko Kirin Co Ltd | A TABLET THAT DISAPPOINTS QUICKLY IN THE MOUTH |
JP4098376B2 (en) * | 1996-09-05 | 2008-06-11 | ビーエーエスエフ ソシエタス・ヨーロピア | Water-soluble vitamin composition having excellent tablet characteristics and method for producing the same |
HUP0000116A3 (en) | 1996-10-01 | 2000-08-28 | Stanford Res Inst Int | Taste-masked microcapsule compositions and methods of manufacture |
EP1070496A4 (en) | 1998-04-08 | 2004-07-21 | Kyowa Hakko Kogyo Kk | Tablet manufacturing method and tablet |
US6740341B1 (en) * | 1998-11-25 | 2004-05-25 | Cima Labs Inc. | Taste masking rapid release coating system |
US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
US6872405B2 (en) * | 2001-05-10 | 2005-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Quick-disintegrating tablet in buccal cavity and manufacturing method thereof |
KR20040023660A (en) * | 2001-07-19 | 2004-03-18 | 파마시아 코포레이션 | Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor |
US6500454B1 (en) | 2001-10-04 | 2002-12-31 | Eurand Pharmaceuticals Ltd. | Timed, sustained release systems for propranolol |
US20040185093A1 (en) * | 2003-03-18 | 2004-09-23 | Szymczak Christopher E. | Compositions containing sucralose |
US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
US8545881B2 (en) | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
WO2006023347A1 (en) * | 2004-08-20 | 2006-03-02 | Alpharma, Inc. | Paroxetine formulations |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
WO2006047493A2 (en) | 2004-10-21 | 2006-05-04 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
US20060105038A1 (en) | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
RU2406481C2 (en) * | 2005-05-26 | 2010-12-20 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Oral composition marking procedure |
WO2007010574A1 (en) | 2005-07-22 | 2007-01-25 | Stmicroelectronics S.R.L. | Integrated pressure sensor with a high full-scale value |
DE102005051951B4 (en) | 2005-09-23 | 2008-01-10 | Beru Ag | Method for tire pressure monitoring in multi-axle vehicles |
ES2576258T3 (en) * | 2005-12-22 | 2016-07-06 | Takeda Pharmaceutical Company Limited | Solid preparation containing an insulin sensitizer |
KR101489401B1 (en) | 2006-01-27 | 2015-02-03 | 앱탈리스 파마테크, 인코포레이티드 | Drug delivery systems comprising weakly basic drugs and organic acids |
CN101410094B (en) | 2006-01-27 | 2013-04-17 | 阿普塔利斯制药股份有限公司 | Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids |
CA2661683C (en) | 2006-08-31 | 2015-11-24 | Eurand, Inc | Drug delivery systems comprising solid solutions of weakly basic drugs |
US8962022B2 (en) * | 2007-03-27 | 2015-02-24 | Aptalis Pharmatech, Inc. | Pharmaceutical compositions comprising an active substance from the substituted benzhydrylpiperazine family |
CL2008003827A1 (en) * | 2007-12-21 | 2009-07-24 | Aptalis Pharmatech Inc | Composition for orally disintegrating tablets comprising at least one drug (temazepam), 0.5-3% of a binder polymer for odt, a sugar alcohol and / or saccharide, and a disintegrant; method to prepare it; Useful to treat a disease or condition such as a sleep disorder in patients with dysphagia. |
TW200938186A (en) * | 2008-02-13 | 2009-09-16 | Eurand Inc | Orally disintegrating tablet compositions of ranitidine and methods of manufacture |
US8133506B2 (en) | 2008-03-12 | 2012-03-13 | Aptalis Pharmatech, Inc. | Drug delivery systems comprising weakly basic drugs and organic acids |
TWI519322B (en) | 2008-04-15 | 2016-02-01 | 愛戴爾製藥股份有限公司 | Compositions comprising weakly basic drugs and controlled-release dosage forms |
JP5878022B2 (en) | 2009-02-23 | 2016-03-08 | アデア ファーマスーティカルズ,インコーポレイテッド | Controlled release composition comprising an anticholinergic agent |
CA2753444A1 (en) | 2009-02-23 | 2010-08-26 | Gopi Venkatesh | Controlled-release compositions comprising a proton pump inhibitor |
TW201041607A (en) | 2009-05-01 | 2010-12-01 | Eurand Inc | Orally disintegrating tablet compositions comprising combinations of non-opioid and opioid analgesics |
-
2010
- 2010-11-23 EP EP10833860.9A patent/EP2506835B1/en not_active Not-in-force
- 2010-11-23 SG SG10201407947WA patent/SG10201407947WA/en unknown
- 2010-11-23 RU RU2012124265/15A patent/RU2012124265A/en unknown
- 2010-11-23 ES ES10833860T patent/ES2739888T3/en active Active
- 2010-11-23 CA CA2782177A patent/CA2782177C/en not_active Expired - Fee Related
- 2010-11-23 JP JP2012541164A patent/JP5854476B2/en not_active Expired - Fee Related
- 2010-11-23 MX MX2012006241A patent/MX337603B/en active IP Right Grant
- 2010-11-23 WO PCT/US2010/057811 patent/WO2011066287A1/en active Application Filing
- 2010-11-23 BR BR112012012999A patent/BR112012012999A2/en not_active IP Right Cessation
- 2010-11-23 NZ NZ600123A patent/NZ600123A/en not_active IP Right Cessation
- 2010-11-23 AU AU2010324835A patent/AU2010324835B2/en not_active Ceased
- 2010-11-25 UY UY0001033062A patent/UY33062A/en not_active Application Discontinuation
- 2010-11-29 TW TW099141291A patent/TWI495491B/en not_active IP Right Cessation
- 2010-11-30 AR ARP100104427A patent/AR079175A1/en unknown
- 2010-11-30 US US12/956,543 patent/US20110129530A1/en not_active Abandoned
-
2012
- 2012-05-29 IL IL220037A patent/IL220037A0/en unknown
- 2012-05-30 CL CL2012001404A patent/CL2012001404A1/en unknown
- 2012-06-05 CO CO12094058A patent/CO6551722A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
UY33062A (en) | 2011-05-31 |
MX337603B (en) | 2016-03-10 |
ES2739888T3 (en) | 2020-02-04 |
BR112012012999A2 (en) | 2019-04-02 |
CL2012001404A1 (en) | 2012-08-17 |
EP2506835A4 (en) | 2014-05-28 |
AU2010324835A1 (en) | 2012-06-14 |
WO2011066287A1 (en) | 2011-06-03 |
CO6551722A2 (en) | 2012-10-31 |
RU2012124265A (en) | 2014-01-20 |
NZ600123A (en) | 2015-04-24 |
TW201124176A (en) | 2011-07-16 |
TWI495491B (en) | 2015-08-11 |
CA2782177C (en) | 2019-10-15 |
MX2012006241A (en) | 2012-06-27 |
JP2013512250A (en) | 2013-04-11 |
AU2010324835B2 (en) | 2015-06-18 |
US20110129530A1 (en) | 2011-06-02 |
EP2506835A1 (en) | 2012-10-10 |
JP5854476B2 (en) | 2016-02-09 |
EP2506835B1 (en) | 2019-06-12 |
CA2782177A1 (en) | 2011-06-03 |
IL220037A0 (en) | 2012-07-31 |
AR079175A1 (en) | 2011-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201407947WA (en) | Compressible-coated pharmaceutical compositions and tablets and methods of manufacture | |
JP5583012B2 (en) | Intraoral quick disintegrating tablet and method for producing the same | |
RU2016144479A (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES MEDIATED BY FLOUR-VISCIDOUS TRANSMEMBRANE CONDUCTIVITY REGULATOR | |
US20070059360A1 (en) | Water-dispersible anti-retroviral pharmaceutical compositions | |
WO2008146178A3 (en) | A novel tablet dosage form | |
JP2022016638A (en) | Pharmaceutical composition containing irbesartan and amlodipine or salt thereof | |
WO2008142572A3 (en) | Controlled release tablet formulation containing magnesium aluminometasilicate | |
JP6245677B2 (en) | Orally disintegrating tablets | |
CN101073563B (en) | Chiral composition containing dextrothyroxine buprofenli and levomethadyl cysteliqin and its double slow-releasing tablet | |
WO2009043926A3 (en) | Oral fast disintegrating tablets | |
UA116334C2 (en) | SOLID FORMS OF BENDAMUSTINE DOSAGE | |
WO2007031887A3 (en) | Extended release pharmaceutical composition of metformin and a process for producing it | |
CA2865380A1 (en) | Solid pharmaceutical composition containing 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof | |
JP2011006446A (en) | Particulate pharmaceutical composition for oral administration of atorvastatin | |
EP3162363B1 (en) | Composite preparation comprising active ingredient-containing film coating layer | |
CA2936108A1 (en) | Novel compositions | |
JP2010143836A (en) | Composition for orally disintegrable tablet | |
WO2008005352A3 (en) | Solid dose formulations of a thrombin receptor antagonist | |
JP5614445B2 (en) | Particulate pharmaceutical composition for oral administration | |
EP2826465B1 (en) | Orally disintegrating tablet formulations of donepezil | |
WO2012161240A1 (en) | Dry-coated tablet containing tegafur, gimeracil and oteracil potassium | |
WO2012056509A1 (en) | Pharmaceutical composition | |
JP2016079102A (en) | Solifenacin-containing formulation | |
US20130085145A1 (en) | Imatinib mesilate pharmaceutical tablet | |
EP2236160A2 (en) | Modified release dimebolin formulations |